Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 6Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 9Thoracic 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Red-Cell Aplasia, Pure 1Breast Neoplasms 1Anemia 1

Interventions

Trastuzumab 87Cyclophosphamide 67Capecitabine 67Paclitaxel 64Docetaxel 58Fulvestrant 52Letrozole 50Carboplatin 42pembrolizumab 41Lapatinib 38Doxorubicin 36Anastrozole 32Vinorelbine 31Bevacizumab 31exemestane 28Tamoxifen 25Gemcitabine 25Albumin-Bound Paclitaxel 25Radiotherapy 21Taxes 19atezolizumab 18pertuzumab 17Everolimus 17130-nm albumin-bound paclitaxel 17Epirubicin 16palbociclib 15Magnetic Resonance Spectroscopy 15eribulin 14Ado-Trastuzumab Emtansine 14Goserelin 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Epoetin Alfa × Breast × Clear all
NCT00246597 2011-05-19

A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer

Ortho Biotech Products, L.P.

Phase 3 Terminated
37 enrolled
BreastClassical hematology

Anemia, Breast Neoplasms, Red-Cell Aplasia, Pure

Data powered by HemOnc (CC BY 4.0) Colophon âš¡